{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T20:28:10Z","timestamp":1760646490791,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.jsat.2016.06.002","type":"journal-article","created":{"date-parts":[[2016,6,6]],"date-time":"2016-06-06T15:28:48Z","timestamp":1465226928000},"page":"62-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection"],"prefix":"10.1016","volume":"68","author":[{"given":"Jeanette M.","family":"Tetrault","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet P.","family":"Tate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. Jennifer","family":"Edelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam J.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Vincent Lo","family":"Re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph K.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Rimland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Goulet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Crystal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie R.","family":"Gaither","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia L.","family":"Gibert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria C.","family":"Rodriguez-Barradas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn E.","family":"Fiellin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kendall","family":"Bryant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy C.","family":"Justice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Fiellin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2016.06.002_bb0005","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0168-8278(00)00050-7","article-title":"Mechanisms for experimental buprenorphine hepatotoxicity: major role of mitochondrial dysfunction versus metabolic activation","volume":"34","author":"Berson","year":"2001","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.jsat.2016.06.002_bb0010","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0168-8278(00)00049-0","article-title":"Hepatitis after intravenous buprenorphine misuse in heroin addicts","volume":"34","author":"Berson","year":"2001","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.jsat.2016.06.002_bb0015","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1080\/00952990701653875","article-title":"Case series on the safe use of buprenorphine\/naloxone in individuals with acute hepatitis C infection and abnormal hepatic liver transaminases","volume":"33","author":"Bruce","year":"2007","journal-title":"American Journal of Drug & Alcohol Abuse"},{"key":"10.1016\/j.jsat.2016.06.002_bb0025","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/QAD.0b013e328013db9c","article-title":"Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy?","volume":"21","author":"Cicconi","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.jsat.2016.06.002_bb0030","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s40266-013-0093-9","article-title":"The next therapeutic challenge in HIV: Polypharmacy","volume":"30","author":"Edelman","year":"2013","journal-title":"Drugs & Aging"},{"key":"10.1016\/j.jsat.2016.06.002_bb0035","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1056\/NEJMoa055255","article-title":"Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence","volume":"355","author":"Fiellin","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"Suppl. 1","key":"10.1016\/j.jsat.2016.06.002_bb0040","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1097\/QAI.0b013e3182097537","article-title":"Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine\/naloxone","volume":"56","author":"Fiellin","year":"2011","journal-title":"JAIDS Journal of Acquired Immune Deficiency Syndromes"},{"issue":"8 Suppl. 2","key":"10.1016\/j.jsat.2016.06.002_bb0045","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1097\/01.mlr.0000223670.00890.74","article-title":"Development and verification of a \"virtual\" cohort using the national VA health information system","volume":"44","author":"Fultz","year":"2006","journal-title":"Medical Care"},{"key":"10.1016\/j.jsat.2016.06.002_bb0050","first-page":"CD002025","article-title":"Buprenorphine for the management of opioid withdrawal","volume":"3","author":"Gowing","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.jsat.2016.06.002_bb0055","first-page":"CD004145","article-title":"Oral substitution treatment of injecting opioid users for prevention of HIV infection","volume":"8","author":"Gowing","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.jsat.2016.06.002_bb0060","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1097\/00042737-200410000-00013","article-title":"Acute hepatitis due to buprenorphine administration","volume":"16","author":"Herve","year":"2004","journal-title":"European Journal of Gastroenterology & Hepatology"},{"key":"10.1016\/j.jsat.2016.06.002_bb0065","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0376-8716(90)90078-S","article-title":"Safety and side-effects of buprenorphine in the clinical management of heroin addiction","volume":"26","author":"Lange","year":"1990","journal-title":"Drug & Alcohol Dependence"},{"key":"10.1016\/j.jsat.2016.06.002_bb0070","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/pds.3470","article-title":"Validity of diagnostic codes to identify cases of severe acute liver injury in the US Food and Drug Administration's mini-sentinel distributed database","volume":"22","author":"Lo Re","year":"2013","journal-title":"Pharmacoepidemiology & Drug Safety"},{"key":"10.1016\/j.jsat.2016.06.002_bb0075","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1521-0391.2013.12052.x","article-title":"Effects of HCV seropositive status on buprenorphine pharmacokinetics in opioid-dependent individuals","volume":"23","author":"Masson","year":"2014","journal-title":"American Journal on Addictions"},{"issue":"Suppl. 1","key":"10.1016\/j.jsat.2016.06.002_bb0080","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1360-0443.2012.04043.x","article-title":"Effect of hepatitis C virus status on liver enzymes in opioid-dependent pregnant women maintained on opioid-agonist medication","volume":"107","author":"McNicholas","year":"2012","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2016.06.002_bb0090","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/10550490050148099","article-title":"Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine","volume":"9","author":"Petry","year":"2000","journal-title":"The American Journal on Addictions"},{"key":"10.1016\/j.jsat.2016.06.002_bb0095","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.drugalcdep.2012.08.002","article-title":"Buprenorphine\/naloxone and methadone effects on laboratory indices of liver health: A randomized trial","volume":"128","author":"Saxon","year":"2013","journal-title":"Drug & Alcohol Dependence"},{"key":"10.1016\/j.jsat.2016.06.002_bb0100","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1521-0391.2014.12131.x","article-title":"Buprenorphine-naloxone treatment in opioid dependence and risk of liver enzyme elevation: Results from a 12-month observational study","volume":"23","author":"Soyka","year":"2014","journal-title":"The American Journal on Addictions"},{"issue":"Suppl. 4","key":"10.1016\/j.jsat.2016.06.002_bb0105","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1086\/508182","article-title":"A trial of integrated buprenorphine\/naloxone and HIV clinical care","volume":"43","author":"Sullivan","year":"2006","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.jsat.2016.06.002_bb0110","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1300\/J465v27n03_03","article-title":"Training HIV physicians to prescribe buprenorphine for opioid dependence","volume":"27","author":"Sullivan","year":"2006","journal-title":"Substance Abuse"},{"key":"10.1016\/j.jsat.2016.06.002_bb0115","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jsat.2012.07.011","article-title":"Brief versus extended counseling along with buprenorphine\/naloxone for HIV-infected opioid dependent patients","volume":"43","author":"Tetrault","year":"2012","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2016.06.002_bb0120","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1089\/cap.2009.0093","article-title":"Buprenorphine-induced elevated liver enzymes in an adolescent patient","volume":"20","author":"Upadhyay","year":"2010","journal-title":"Journal of Child & Adolescent Psychopharmacology"},{"issue":"Suppl. 1","key":"10.1016\/j.jsat.2016.06.002_bb0125","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1097\/QAI.0b013e31820a820f","article-title":"Hepatic safety and lack of antiretroviral interactions with buprenorphine\/naloxone in HIV-infected opioid-dependent patients","volume":"56","author":"Vergara-Rodriguez","year":"2011","journal-title":"Journal of Acquired Immune Deficiency Syndromes: JAIDS"},{"key":"10.1016\/j.jsat.2016.06.002_bb0130","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1001\/archgenpsychiatry.2011.121","article-title":"Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: A 2-phase randomized controlled trial","volume":"68","author":"Weiss","year":"2011","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.jsat.2016.06.002_bb0135","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/j.dld.2007.12.014","article-title":"Acute liver and renal failure during treatment with buprenorphine at therapeutic dose","volume":"41","author":"Zuin","year":"2009","journal-title":"Digestive & Liver Disease"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547215300349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547215300349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:44:49Z","timestamp":1760039089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547215300349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":25,"alternative-id":["S0740547215300349"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2016.06.002","relation":{},"ISSN":["0740-5472"],"issn-type":[{"type":"print","value":"0740-5472"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2016.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}